<ѻýҕl>'Practice Changing' Trial for Inoperable Locally Advanced NSCLCѻýҕl> EGFR testing now needed for all patients with stage III disease, experts say Jun 02, 2024
<ѻýҕl>Intralesional Therapy for Melanoma Effective, May Have Systemic Activityѻýҕl> Preoperative antibody fusion daromun significantly reduced relapse versus upfront surgery Jun 02, 2024
<ѻýҕl>Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myelomaѻýҕl> Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
<ѻýҕl>Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancerѻýҕl> No differences observed in quality of life metric, patient and caregiver satisfaction Jun 02, 2024
<ѻýҕl>No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLCѻýҕl> Results are "disappointing as we need better therapies in the refractory space," expert says Jun 02, 2024
<ѻýҕl>Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLCѻýҕl> Unexpectedly offers a possible overall survival benefit, researchers say Jun 01, 2024
<ѻýҕl>Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agentsѻýҕl> China-based trial may present a hurdle to FDA approval, however Jun 01, 2024
<ѻýҕl>Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trialѻýҕl> Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity Jun 01, 2024
<ѻýҕl>Unprecedented PFS Results in ALK-Positive Lung Cancer Trialѻýҕl> "We have not seen anything close to this," says expert May 31, 2024
<ѻýҕl>STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CMLѻýҕl> The benefit-risk profile could change the treatment paradigm in CML, expert says May 31, 2024
<ѻýҕl>HPV Vaccination Reduces Risk of Multiple Types of Cancer in Men and Womenѻýҕl> Large cohort study provides some of the first evidence of cancer reduction after vaccination May 24, 2024
<ѻýҕl>Most Women Can Have Successful Pregnancies After Breast Cancer Treatmentѻýҕl> Fertility preservation before treatment strongly predictive of live births, study shows May 24, 2024
<ѻýҕl>Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Riskѻýҕl> Incidence, mortality double over 20 years, while estrogen plus MPA lowers endometrial cancer risk May 24, 2024
<ѻýҕl>TTFields Therapy Yields OS Improvement in Second-Line NSCLCѻýҕl> However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<ѻýҕl>Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancerѻýҕl> No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
<ѻýҕl>Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remissionѻýҕl> PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
<ѻýҕl>FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancerѻýҕl> Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says Jun 07, 2023
<ѻýҕl>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLCѻýҕl> "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<ѻýҕl>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Yearsѻýҕl> Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
<ѻýҕl>No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCCѻýҕl> The strategy also led to increased toxicity Jun 06, 2023
<ѻýҕl>New Data in NSCLC Bolster Support for Perioperative Immunotherapyѻýҕl> EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
<ѻýҕl>Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphomaѻýҕl> The CAR T-cell therapy led to significantly longer overall survival Jun 05, 2023
<ѻýҕl>New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trialsѻýҕl> High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
<ѻýҕl>CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myelomaѻýҕl> Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
<ѻýҕl>T-DXd Proves Mettle in Multiple Solid Tumorsѻýҕl> Data from ongoing DPT02 trial show broad activity in HER2-expressing advanced disease Jun 05, 2023
<ѻýҕl>Omitting RT Safe in Many Locally Advanced Rectal Cancersѻýҕl> Most intermediate-risk cases can be cured without pelvic radiation, says investigator Jun 05, 2023
<ѻýҕl>Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Gliomaѻýҕl> INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert Jun 04, 2023
<ѻýҕl>Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphomaѻýҕl> SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease Jun 04, 2023
<ѻýҕl>New Standard in Operable EGFR-Positive Lung Cancerѻýҕl> "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
<ѻýҕl>New Ovarian Cancer Drug Extends Survival in Resistant Diseaseѻýҕl> "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
<ѻýҕl>Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancerѻýҕl> Survival 13 months better with surgery, but "curiosities" in neoadjuvant arm muddy the results Jun 04, 2023
<ѻýҕl>Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancerѻýҕl> Response rates reached 41-47% with different approaches in rare disease Jun 03, 2023
<ѻýҕl>Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancerѻýҕl> Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET Jun 03, 2023
<ѻýҕl>Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancerѻýҕl> Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib Jun 03, 2023
<ѻýҕl>De-Escalated Surgery Suffices for Low-Risk Cervical Cancerѻýҕl> Simple hysterectomy non-inferior to radical operation Jun 02, 2023
<ѻýҕl>CDK4/6 Extends Reach Into Early-Stage Breast Cancerѻýҕl> Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease Jun 02, 2023
<ѻýҕl>Trial Results Spark Talk of Curing More Metastatic Cervical Cancersѻýҕl> Adding pembrolizumab to standard care extends overall survival by a year May 25, 2023
<ѻýҕl>Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patientsѻýҕl> 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
<ѻýҕl>Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDSѻýҕl> Results suggest a "paradigm shift" in the treatment of anemia for these patients May 25, 2023
<ѻýҕl>Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effectiveѻýҕl> Radical resection rate noninferior to open surgery in early-stage disease, with similar survival May 25, 2023